Cargando…
Medications in type-2 diabetics and their association with liver fibrosis
BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is significantly rising worldwide. Type-2 diabetes (T2D) is a major risk factor for NAFLD progression. AIM: To assess the association of commonly used medications to advanced fibrosis (AF) in patients with biopsy-proven NAFLD and...
Autores principales: | Siddiqui, Mohamed Tausif, Amin, Hina, Garg, Rajat, Chadalavada, Pravallika, Al-Yaman, Wael, Lopez, Rocio, Singh, Amandeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336333/ https://www.ncbi.nlm.nih.gov/pubmed/32684739 http://dx.doi.org/10.3748/wjg.v26.i23.3249 |
Ejemplares similares
-
Natural history of gastrointestinal schwannomas
por: Singh, Amandeep, et al.
Publicado: (2022) -
Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022) -
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease
por: Ayoub, Fares, et al.
Publicado: (2018) -
Impact of biliary complications on quality of life in live-donor liver transplant recipients
por: Guirguis, Reginia Nabil, et al.
Publicado: (2021) -
Does serotonin reuptake inhibitor therapy increase the risk of post-sphincterotomy bleeding in patients undergoing endoscopic retrograde cholangio-pancreatography?
por: Yadav, Divya, et al.
Publicado: (2017)